search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


The role of dopamine and noradrenaline in probability and reward value processing.


- candidate number21758
- NTR NumberNTR5019
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR4-mrt-2015
- Secondary IDsNL51144.041.14 
- Public TitleThe role of dopamine and noradrenaline in probability and reward value processing.
- Scientific TitleThe role of dopamine and noradrenaline in probability and reward value processing.
- ACRONYM
- hypothesisWe hypothesize that the brain dopamine system plays a role in subjective probability processing and we hypothesize that both the brain dopamine and noradrenaline system play a role in subjective value processing.
- Healt Condition(s) or Problem(s) studiedDopamine antagonism, Noradrenaline antagonism, Subjective probability processing, Subjective value processing
- Inclusion criteriaMale, non-smoking, age between 18-45 years and passing the screening (assessing medical history and blood pressure/heart rate)
- Exclusion criteriaPsychopathology, current medication use, (history of) serious medical condition(s), low blood pressure, heart rate above 100 bpm or below 60 bpm in rest.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupCrossover
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-mei-2015
- planned closingdate29-apr-2016
- Target number of participants36
- Interventions- one capsule containing 150 microgram clonidine
- one capsule containing 2 milligram haloperidol
- one capsule containing placebo
- Primary outcomeCue specific P200 event-related potential relative to no cue, cue specific P300 event-related potential relative to no cue. Independent variables: Subjective value, Subjective probability, dopaminergic antagonism by haloperidol and noradrenergic antagonism by clonidine.
- Secondary outcome- Velocity scaling measurement
- Spontaneous motor activity measurement
- Event related potentials in response to the target
- Reaction times in response to the target
- Target omissions and percentage correct responses
- Questionnaire scores (attentional control, State-trait anxiety inventory)
- TimepointsParticipants will be tested during 3 separate sessions.
Measurements will be made 3 hours after capsule intake.
- Trial web site
- statusplanned
- CONTACT FOR PUBLIC QUERIESMsc. Iris Schutte
- CONTACT for SCIENTIFIC QUERIESMsc. Iris Schutte
- Sponsor/Initiator Utrecht University (UU)
- Funding
(Source(s) of Monetary or Material Support)
NWO
- Publications
- Brief summary
- Main changes (audit trail)
- RECORD4-mrt-2015 - 15-apr-2015


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl